^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    abiraterone acetate

    i
    Other names: CB 7630, JNJ-212082, CB-7630, CB7630, BR9004
    Company:
    Generic mfg.
    Drug class:
    CYP17A1 inhibitor
    Related drugs:
    18h
    Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer (clinicaltrials.gov)
    P2, N=200, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    Zejula (niraparib) • abiraterone acetate • apalutamide
    22h
    Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) (clinicaltrials.gov)
    P1/2, N=1200, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • carboplatin • docetaxel • Lenvima (lenvatinib) • enzalutamide • abiraterone acetate • etoposide IV • prednisone • dexamethasone • Welireg (belzutifan) • vibostolimab/pembrolizumab (MK-7684A)
    3d
    Direct Androgen Receptor Antagonism Enhances Therapeutic PSMA Radioligand Uptake in Prostate Cancer Models. (PubMed, Mol Imaging Biol)
    Direct AR antagonism enhances functional PSMA availability and increases short-term uptake of PSMA-targeted radioligands in AR-positive prostate cancer models. These findings provide mechanistic support for AR-mediated modulation of PSMA-targeted radioligand delivery and warrant further translational investigation.
    Preclinical • Journal
    |
    AR (Androgen receptor) • FOLH1 (Folate hydrolase 1)
    |
    AR positive • FOLH1 expression
    |
    enzalutamide • abiraterone acetate • apalutamide
    5d
    PROpelSub: Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort) (clinicaltrials.gov)
    P3, N=110, Active, not recruiting, AstraZeneca | Trial completion date: Apr 2026 --> Feb 2027
    Trial completion date
    |
    HRD (Homologous Recombination Deficiency)
    |
    Lynparza (olaparib) • abiraterone acetate
    8d
    Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial (clinicaltrials.gov)
    P2, N=202, Not yet recruiting, Mayo Clinic
    New P2 trial
    |
    abiraterone acetate • Eligard (leuprolide acetate) • Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Viadur (leuprorelin implant) • Yonsa (abiraterone acetate)
    13d
    Effects of androgen receptor signaling inhibitors on absorbed doses in mCRPC patients undergoing [177Lu]Lu-PSMA-617 or [177Lu]Lu-PSMA-I&T therapy: dosimetry results. (PubMed, Eur J Nucl Med Mol Imaging)
    In this pilot cohort, concomitant ARSi therapy did not significantly enhance tumor absorbed doses in patients receiving [177Lu]Lu-PSMA-617 or [177Lu]Lu-PSMA-I&T RLT. Further prospective studies with larger patient numbers are needed to evaluate the impact of concomitant ARSi treatment on the absorbed doses in mCRPC tumor lesions.
    Journal
    |
    FOLH1 (Folate hydrolase 1) • ARSI (Arylsulfatase Family Member I)
    |
    FOLH1 expression
    |
    enzalutamide • abiraterone acetate • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    13d
    A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov)
    P2/3, N=180, Not yet recruiting, Sichuan Baili Pharmaceutical Co., Ltd.
    New P2/3 trial
    |
    Lynparza (olaparib) • abiraterone acetate • izalontamab brengitecan (BL-B01D1)
    16d
    Neuroendocrine Transformation Without PSA Elevation in High-Risk Metastatic Castration-Sensitive Prostate Cancer Under Androgen Receptor Signaling Inhibition: A Case Report. (PubMed, IJU Case Rep)
    Abiraterone acetate was initiated immediately...Autopsy revealed widespread metastases, all histologically confirmed as neuroendocrine prostate cancer. Strong androgen receptor suppression in metastatic castration-sensitive prostate cancer can lead to aggressive radiographic progression without prostate-specific antigen elevation, underscoring the limitations of antigen-based monitoring.
    Journal
    |
    AR (Androgen receptor)
    |
    abiraterone acetate
    16d
    Real-world comparison of androgen receptor pathway ınhibitors versus docetaxel as first-line treatment in metastatic hormone-sensitive prostate cancer. (PubMed, Curr Med Res Opin)
    We retrospectively analyzed 148 patients with mHSPC treated with either ARPI (abiraterone, enzalutamide, or apalutamide) plus androgen deprivation therapy (ADT) (n = 98) or docetaxel plus ADT (n = 50). In this real-world cohort, ARPI-based therapy was associated with an improvement in rPFS compared with docetaxel, while OS outcomes remained comparable. In the absence of direct randomized comparisons, these findings may provide supportive real-world evidence for the clinical relevance of ARPI-based therapy as a first-line treatment option for patients with mHSPC.
    Journal • Real-world evidence
    |
    AR (Androgen receptor)
    |
    docetaxel • enzalutamide • abiraterone acetate • apalutamide
    20d
    Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT) (clinicaltrials.gov)
    P2, N=132, Recruiting, University Health Network, Toronto | Trial completion date: Mar 2026 --> Feb 2031 | Trial primary completion date: Mar 2026 --> Feb 2031
    Trial completion date • Trial primary completion date
    |
    enzalutamide • abiraterone acetate
    21d
    CHAARTED2: Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel (clinicaltrials.gov)
    P2, N=223, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Trial completion date: Apr 2026 --> Apr 2028
    Trial completion date
    |
    docetaxel • abiraterone acetate • prednisone • cabazitaxel